Mounjaro™ (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Tirzepatide: Use in Patients With Gastroparesis

Tirzepatide has not been studied in people with delayed gastric emptying.


Detailed Information

There is no information on the use of tirzepatide in people with gastroparesis because patients were excluded from tirzepatide clinical trials if they had a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction).

Date of Last Review: February 05, 2021

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical